An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX (Sumatriptan) Nasal Spray, 100 mg IMITREX (Sumatriptan) Oral Tablet and 6 mg IMITREX (Sumatriptan) Subcutaneous Injection in Healthy Subjects.

Trial Profile

An Open-Label, Single-Dose, Randomized, Crossover Study to Compare the Bioavailability of the Intranasal Administration of 20 mg OPTINOSE SUMATRIPTAN With 20 mg IMITREX (Sumatriptan) Nasal Spray, 100 mg IMITREX (Sumatriptan) Oral Tablet and 6 mg IMITREX (Sumatriptan) Subcutaneous Injection in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2013

At a glance

  • Drugs Sumatriptan (Primary) ; Sumatriptan (Primary) ; Sumatriptan (Primary)
  • Indications Migraine
  • Focus Pharmacokinetics
  • Most Recent Events

    • 28 Jun 2013 Results presented at the 2013 International Headache Congress, according to an Optinose media release.
    • 02 Oct 2012 Results have been reported in an OptiNose media release.
    • 28 Feb 2012 Actual patients number is 20 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top